LGALSL

Across TCGA pan-cancer cohorts, LGALSL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LGALSL data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LGALSL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LGALSL expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where LGALSL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.904	0.204	<.001	33	view →
HNSC	OS	Median	II,III,IV	0.903	0.799	.038	11	view →
PDAC	DFS	Quartile	All	0.571	0.349	.019	10	view →
LUAD	OS	Median	All	1.000	0.787	.011	6	view →
UCEC	OS	Quartile	All	1.000	0.888	.029	4	view →
GBM	DFS	Quartile	All	0.844	0.609	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LGALSL–CCRCC (DFS)

Open the CCRCC breakdown →